Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy
- 15 March 2016
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 55 (9) , 1031-1043
Abstract
Voriconazole is a potent antifungal agent used for the treatment of invasive fungal infections caused by Aspergillus and Candida species in adult and pediatric patients. Voriconazole has a narrow therapeutic index and a large intra- and inter-individual pharmacokinetics (PK) variability. Several factors including non-linear PK, age, body weight, cytochrome P450 2C19 genotype, concomitant drugs, liver function, and food are responsible for the large variability in voriconazole PK. A combination of a narrow therapeutic index with a large PK variability results in treatment failure in many patients at clinically recommended doses. There is an urgent need to establish an optimal dosing regimen for pediatric patients 60 %) treatment failure rates. Therapeutic drug monitoring is commonly used in clinical practice to optimize the voriconazole dosing regimens in pediatric patients, but it is associated with several practical limitations. Implementation of a PK model-guided individualized dose selection will help in reducing the PK variability and will improve therapeutic outcomes. In this review, we have summarized the covariates influencing the PK of voriconazole in adult and pediatric patients, emphasizing that the clearance of voriconazole is significantly different between adult and pediatric patients owing to developmental changes in the major clearance pathways. Moreover, we have provided the limitations of the current dosing regimens and have proposed a new dosing method using a PK model-guided dose individualization of voriconazole in pediatric patients.Keywords
This publication has 90 references indexed in Scilit:
- Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and AdultsAntimicrobial Agents and Chemotherapy, 2012
- Population Pharmacokinetics of Voriconazole in AdultsAntimicrobial Agents and Chemotherapy, 2012
- Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy AdultsAntimicrobial Agents and Chemotherapy, 2011
- Evaluating Performance of a Decision Support System to Improve Methotrexate Pharmacotherapy in Children and Young Adults With CancerTherapeutic Drug Monitoring, 2011
- Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised ChildrenAntimicrobial Agents and Chemotherapy, 2010
- Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismEuropean Journal of Clinical Pharmacology, 2010
- Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17British Journal of Clinical Pharmacology, 2010
- Voriconazole Pharmacokinetics and Pharmacodynamics in ChildrenClinical Infectious Diseases, 2010
- Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotypeBritish Journal of Clinical Pharmacology, 2009
- Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric StudiesAntimicrobial Agents and Chemotherapy, 2009